ABSTRACT Background: We consider how many cannabis users may need to be prevented in order to prevent one case of schizophrenia or psychosis [defined as number needed to prevent (NNP)]. Method: Calculation for England and Wales using best available estimates of: incidence of schizophrenia; rates of heavy and light cannabis use; and risk that…
Read More »Any clinical discussion on medical cannabis is limited by the relative paucity of randomized controlled trials. Only a small number of clinical studies involving the therapeutic use of cannabis have been carried out to date. And, of those studies, only short term adverse effects associated with cannabis use have been evaluated. In general, the medical…
Read More »Doctors with the U.S. Department of Veterans Affairs still can’t recommend medical marijuana, but they are being encouraged to talk more about it with military veterans.
Read More »https://www.ncbi.nlm.nih.gov/pubmed/17185040 Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune system, respectively, and mediate a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. In this study, we investigated the immunosuppressive properties of JWH-015, a synthetic CB2-selective…
Read More »